- Trial phase
- Approved
- Time to market
- Already approved and launched commercially as of September 2026.
- Why 4/10
- FAYUVI was approved by the FDA on September 17, 2026, so the defining binary regulatory event has passed. There is no pending PDUFA or pivotal readout for this drug in the next ~12 months. As an approved, marketed product, the next catalysts are commercial execution (revenue ramp, payer reimbursement) which are not hard binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
With the approval binary behind it, FAYUVI's investor focus shifts to commercial execution: Q4 2026 and early 2027 revenue disclosures, payer reimbursement decisions, and the number of patients dosed. The stock's 52-week range ($12.73-$39.89) and recent cost-cutting plan suggest the market is pricing in execution risk. Watch for early revenue signals from the Q4 2026 earnings report and any updates on treatment center activations.
Price Chart
Executive Summary
FAYUVI (rebisufligene etisparvovec, formerly UX111) is a one-time AAV9 gene therapy from Ultragenyx Pharmaceutical (NASDAQ: RARE) that won FDA standard approval on September 17, 2026, as the first-ever treatment for Sanfilippo syndrome type A (MPS IIIA), a fatal pediatric neurodegenerative disease. Priced at $3.95 million per dose, it is Ultragenyx's second gene therapy approval and came with a Priority Review Voucher sold for $203 million. The approval followed a prior rejection in 2025 over manufacturing issues. While the drug addresses a high-unmet-need orphan population and has no direct competition, commercial adoption of a $4 million ultra-rare gene therapy is unproven, and the company is simultaneously cutting costs and pipeline programs to reach profitability by 2027.
How It Works
FAYUVI is a one-time gene therapy that delivers a working copy of the SGSH gene into cells using a harmless AAV9 virus shell. In children with Sanfilippo syndrome type A, a mutation in the SGSH gene causes a toxic sugar molecule (heparan sulfate) to build up in the brain, progressively destroying neurons. The therapy aims to restore the missing enzyme and stop or slow that damage.
Trial Status
FAYUVI was approved by the FDA on September 17, 2026, based on an open-label Phase 1/2/3 trial (NCT02716246 and follow-up studies) in children ages 2-5 with preserved neurodevelopmental function. The trial measured cognitive development against a natural-history control group. Treated patients scored roughly 23.5 points higher on cognitive testing than untreated peers, per published reports. The most common adverse reactions were elevated liver enzymes, nausea, vomiting, and fever.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 / early 2027 commercial launch revenue updates and payer access progress
- Expansion into additional international markets (EMA filing)
- Longer-term follow-up data from the ongoing clinical trial
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ultragenyx Pharmaceutical Inc. PRESS-RELEASE RARE ·Originating report